Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising its annual revenue and earnings guidance for the year. The pharmaceutical giant, known for its blockbuster COVID-19 products, is now forging ahead with a diversified growth strategy, reflecting a well-balanced portfolio of oncology, cardiology, and other in-demand […]
Seagen Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase 3 EV-302 clinical trial, presenting PADCEV in combination with KEYTRUDA versus chemotherapy. This potent combination significantly improved overall survival (OS) and progression-free survival (PFS) for patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Highlighted Findings from the EV-302 Study […]
American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, in a move to strengthen its position in the oncology space. With the proposed acquisition, Pfizer anticipates broadening its oncology portfolio by adding Seagen’s medicines, late-stage development programs, and antibody-drug […]